Abstract
Although several case series of primary signet-ring cell adenocarcinoma (SRCA) of the urinary bladder (UB) have been published, primary pure SRCA of the UB composed exclusively of signet-ring cells is rare. In addition, there have been no comprehensive studies of immunohistochemical studies of primary SRCA of the UB. This report shows immunohistochemical profiles of 3 cases of primary SRCA of UB. The age of patients was 37, 43, and 84 years. The male-to-female ratio was 2:1. One specimen was cystectomy, and other two specimens were transurethral bladder tumorectomy. Two patients died of bladder tumor 12 and 16 months after the diagnosis, and one patient is now alive 6 months after the diagnosis. Histologically, all the three tumors were composed exclusively of SRCA cells. Histochemically, all tumors contained neutral and acidic mucins. Immunohistochemically, consistent findings were positive cytokeratin (CK) AE1/3, CK CAM5.2, CK8, CK18, CK19, CK20, p53, Ki-67 (30, 50, 70%), MUC1, and MUC2. CK34BE12, CK5/6, CK14, EMA, p63, vimentin, and MUC6 were consistently negative. CK7 was positive in 1/3, CA19-9 1/3, and MUC5AC 2/3 cases. These data may provide basic knowledge of SRCA of the UB. In conclusion, the author presents three cases of primary pure SRCA with an emphasis of immunohistochemical findings.
Similar content being viewed by others
References
Choi H, Lamb S, Pintar K, Jacobs SC. Primary signet ring cell carcinoma of the urinary bladder. Cancer. 1984;53:1985–90.
DeFillipo N, Blute R, Klein LA. Signet-sing cell carcinoma of the bladder: evaluation of three cases with review of literature. Urology. 1987;29:479–83.
Blute ML, Engen DE, Travis WD, Kvols LK. Primary signet ring cell adenocarcinoma of the bladder. J Urol. 1989;141:17–21.
Grignon DJ, Ro JY, Ayala AG, Johnson DE. Primary signet-ring cell carcinoma of the urinary bladder. Am J Clin Pathol. 1991;95:13–20.
Torenbeek R, Koot RA, Blomjous CE, De Bruin PC, Newling DW, Meijer CJ. Primary signet-sing cell carcinoma of the urinary bladder. Histopathology. 1996;28:33–40.
Kunze E, Krassenkova I, Fayyazi A. Tumor-associated neoexpression of the pS2 peptide and MUC5AC mucin in primary adenocarcinoma and signet ring cell carcinoma of the urinary bladder. Histol Histopathol. 2008;23:539–48.
Del Sordo R, Bellezza G, Colella R, Mameli MG, Sidoni A, Cavaliere A. Primary signet-ring cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 5 cases. Appl Immunohistochem Mol Morphol. 2009;17:18–22.
Thomas AA, Stephenson AJ, Campbell SC, Jones JS, Hansel DE. Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. Hum Pathol. 2009;40:108–16.
Wang J, Wang FW. Clinical characteristics and outcome of patients with primary signet-ring cell carcinoma of the urinary bladder. Urol Int 2011 [Epub ahead of print].
Ayara AG, Oliva E, Tamboil P. Adenocarcima of urinary bladder. In: Eble JN, Sauter vG, Epstein JL, Sesterhenn IA editors. World Health Organization Clasification of Tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004. Pp. 128–30.
Murphy WM, Grignon DJ, Perlman EJ. Adenocarcinoma of the urinary bladder. In: Murphy WM, Grignon DJ, Perlman EJ, editors. AFIP Atlas of tumor of tumor pathology. Series 4. Tumors of the kidney, bladder, and related urinary structures. Whashington, DC: American Registry of Pathology; 2004. pp. 304–8.
Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int. 2002;52:740–6.
Terada T, Kawaguchi M. Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med. 2005;206:271–5.
Conflict of interest
The author has no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Terada, T. Primary pure signet-ring cell adenocarcinoma of the urinary bladder: a report of three cases with an immunohistochemical study. Med Oncol 29, 2866–2869 (2012). https://doi.org/10.1007/s12032-011-0122-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-011-0122-7